Whitcroft Katherine Lisa, Sharma Anup
St George's Healthcare NHS Trust, London, UK.
BMJ Case Rep. 2014 Mar 11;2014:bcr2013203225. doi: 10.1136/bcr-2013-203225.
Surgical parathyroidectomy is the only curative treatment for primary hyperparathyroidism. As minimally invasive parathyroidectomy increases in popularity, so does reliance on preoperative parathyroid localisation techniques. One such technique is sestamibi scintigraphy. We report a case of false-positive sestamibi scintigraphy caused by follicular variant of papillary thyroid carcinoma. Subsequent completion thyroidectomy was not possible due to widespread postoperative fibrosis. This case, therefore, highlights the potential dangers of false-positive results due to thyroid carcinoma and encourages surgeons to consider this possibility when faced with intrathyroidal or otherwise ambiguous parathyroid localisation results.
手术切除甲状旁腺是原发性甲状旁腺功能亢进的唯一治愈性治疗方法。随着微创甲状旁腺切除术越来越受欢迎，对术前甲状旁腺定位技术的依赖也在增加。一种这样的技术是锝[99mTc]甲氧基异丁基异腈闪烁扫描术（sestamibi闪烁扫描）。我们报告一例由甲状腺乳头状癌滤泡变体导致的sestamibi闪烁扫描假阳性病例。由于术后广泛纤维化，后续无法完成甲状腺切除术。因此，该病例突出了甲状腺癌导致假阳性结果的潜在危险，并鼓励外科医生在面对甲状腺内或其他不明确的甲状旁腺定位结果时考虑这种可能性。
